Peliglitazar racemate is primarily investigated for its potential therapeutic applications in metabolic disorders, particularly type 2 diabetes and dyslipidemia. It functions as a dual agonist of peroxisome proliferator-activated receptors (PPARs), specifically PPAR-alpha and PPAR-gamma, which play key roles in regulating glucose and lipid metabolism. By activating these receptors, it helps improve insulin sensitivity, reduce blood glucose levels, and normalize lipid profiles, making it a promising candidate for managing metabolic syndrome. Its development aims to address the limitations of existing therapies by offering a more comprehensive approach to controlling both hyperglycemia and dyslipidemia simultaneously. However, its clinical use is still under research, with studies focusing on efficacy, safety, and potential side effects.